Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial (Q34624732)

3 August 2017

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

31

Anthony S Fauci

1 reference

3 August 2017

Amy Nelson

6

0 references

Michael A. Polis

Michael A Polis

30

0 references

David E. Kleiner

David Kleiner

24

0 references

Anuoluwapo Osinusi

1

Anuoluwapo Osinusi

1 reference

3 August 2017

21

Robin Dewar

1 reference

3 August 2017

10

Michael Proschan

1 reference

3 August 2017

Shyamasundaran Kottilil

33

Shyamasundaran Kottilil

1 reference

3 August 2017

4

Dimitra Bon

1 reference

3 August 2017

18

Colleen Kotb

1 reference

3 August 2017

17

Rachel Silk

1 reference

3 August 2017

32

Henry Masur

1 reference

3 August 2017

16

Rohit Talwani

1 reference

3 August 2017

Eric G Meissner

2

1 reference

3 August 2017

Yu-Jin Lee

3

1 reference

3 August 2017

Laura Heytens

5

1 reference

3 August 2017

Michael Sneller

7

1 reference

3 August 2017

Anita Kohli

8

1 reference

3 August 2017

Lisa Barrett

9

1 reference

3 August 2017

Eva Herrmann

11

1 reference

3 August 2017

Bhavana Shivakumar

12

1 reference

3 August 2017

Wenjuan Gu

13

1 reference

3 August 2017

Richard Kwan

14

1 reference

3 August 2017

Geb Teferi

15

1 reference

3 August 2017

Susan Wroblewski

19

1 reference

3 August 2017

Dawn Fishbein

20

1 reference

3 August 2017

Helene Highbarger

22

1 reference

3 August 2017

Xiao Zhang

23

1 reference

3 August 2017

Brad J Wood

25

1 reference

3 August 2017

Jose Chavez

26

1 reference

3 August 2017

William T Symonds

27

1 reference

3 August 2017

Mani Subramanian

28

1 reference

3 August 2017

John McHutchison

29

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

The Journal of the American Medical Association

3 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

3 August 2017

310

1 reference

3 August 2017

804-811

1 reference

3 August 2017

8

1 reference

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Preliminary study of two antiviral agents for hepatitis C genotype 1.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Telaprevir for previously untreated chronic hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Boceprevir for previously treated chronic HCV genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Boceprevir for untreated chronic HCV genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Telaprevir for previously treated chronic HCV infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

The burden of hepatitis C in the United States

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Exploratory study of oral combination antiviral therapy for hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Modeling HCV kinetics under therapy using PK and PD information

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Triphasic decline of hepatitis C virus RNA during antiviral therapy

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4254410

26 October 2018

Identifiers

DOI

10.1001/JAMA.2013.109309

1 reference

3 August 2017

1 reference

3 August 2017

1 reference